CN114539092B - Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products - Google Patents

Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products Download PDF

Info

Publication number
CN114539092B
CN114539092B CN202210248498.8A CN202210248498A CN114539092B CN 114539092 B CN114539092 B CN 114539092B CN 202210248498 A CN202210248498 A CN 202210248498A CN 114539092 B CN114539092 B CN 114539092B
Authority
CN
China
Prior art keywords
oat bran
amide alkaloid
phenolic
alkaloid
phenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210248498.8A
Other languages
Chinese (zh)
Other versions
CN114539092A (en
Inventor
刘晓宇
刘杰
牛文芳
王怀玲
郑曼
龚苗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Haichuang Biotechnology Co ltd
Original Assignee
Shenzhen Haichuang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Haichuang Biotechnology Co ltd filed Critical Shenzhen Haichuang Biotechnology Co ltd
Priority to CN202210248498.8A priority Critical patent/CN114539092B/en
Publication of CN114539092A publication Critical patent/CN114539092A/en
Application granted granted Critical
Publication of CN114539092B publication Critical patent/CN114539092B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to the technical field of pharmaceutical chemistry, and particularly discloses an oat bran phenol amide alkaloid, a preparation method thereof and application thereof in preparing antipruritic products. The oat bran phenolic amide alkaloid has a structure shown in a formula I or a formula II. The preparation method of the oat bran phenolic amide alkaloid specifically comprises the following steps: taking a reaction substrate caffeic acid analogue, adding an organic solvent, adding 4- (2-aminoethyl) phenol and triethylamine under stirring, and adding HATU after 3-6 minutes; after the addition is finished, continuing to react for 3 to 6 hours at room temperature, and monitoring the disappearance of the reaction raw materials by TLC; stopping stirring, evaporating the solvent under reduced pressure, and purifying the residue by silica gel column chromatography to obtain the oat bran phenolic amide alkaloid. Researches show that the oat bran phenolic amide alkaloid or the composition thereof has excellent antipruritic effect; thus, the oat bran amide alkaloids or compositions thereof may be used for developing antipruritic products.

Description

Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products
Technical Field
The invention relates to the technical field of pharmaceutical chemistry, in particular to oat bran phenol amide alkaloid, a preparation method thereof and application thereof in preparing antipruritic products.
Background
Cutaneous pruritus is the most common skin disorder of the elderly, and antihistamines are common drugs for clinically treating cutaneous pruritus. The balance of Th1/Th2 cells is closely related to abnormal expression of inflammatory factors of patients with cutaneous pruritus, and abnormal expression of Th1 cell factors with obviously increased inflammatory factors is found to play an important role in the etiology of cutaneous pruritus in a rat model of atopic dermatitis, so that the anti-inflammatory therapeutic agent has a good effect on clinical curative effects of cutaneous pruritus.
The traditional Chinese medicine has long history of treating skin diseases, has rich experience, can control recurrent skin diseases or prolong the recurrence time of the recurrent skin diseases, lightens or avoids the side effect of chemical medicines, delays the lesion progress and prolongs the survival time, so the trend of pursuing the traditional Chinese medicine with stable curative effect, safety and reliability is more obvious.
Oats are one of the major cereals worldwide and are recognized by the U.S. FDA as functional foods as an important source of proteins, vitamins and various mineral elements. Studies have shown that oat is rich in a variety of active ingredients, wherein avenanthramides are the main functional ingredients in oat, and have the functions of reducing blood fat, reducing blood sugar, reducing blood pressure and the like, which are all related to the antioxidation effect. In addition, avenanthramides can mediate inflammatory cell responses through interactions with cytokines and signaling pathways, have anti-inflammatory and antibacterial effects, and colloidal extracts containing avenanthramides have demonstrated antihistaminic and anti-inflammatory activity. Oat alkaloids have a variety of biological activities and are very beneficial to human and animal health. And the oat alkaloid has a single structure, and the application is greatly limited by factors such as low content of oat. Therefore, the improvement and optimization are carried out based on the avenanthramide structure, the synthesis of the analogues with the avenanthramide structure or the avenanthramide compounds with better activity is carried out, and the development of the avenanthramide analogues with anti-skin itch has important application value.
Disclosure of Invention
In view of the above, the invention firstly provides an oat bran phenolic amide alkaloid with a brand new structure, and researches show that the oat bran phenolic amide alkaloid has an antipruritic effect.
The detailed technical scheme of the invention is as follows:
an oat bran phenolic amide alkaloid having a structure of formula I or formula ii:
wherein R in formula I or I 1 、R 2 And R is 3 Are respectively and independently selected from H, OH or OCH 3 。
Preferably, the oat bran phenolic amide alkaloid is selected from any one of oat bran phenolic amide alkaloids-1-6; the structural formula of the oat bran phenolic amide alkaloid-1-6 is as follows:
the inventors have found in the study that R in the compound of the formula I or the structure of the formula II 1 、R 2 And R is 3 Oat bran phenolic amide alkaloids obtained after substitution by different groups, the antipruritic effect of which is greatly different; the inventor surprisingly found in the research that the itching relieving effect of the oat bran amide alkaloid-3 is far greater than that of other compounds, and has very remarkable itching relieving effect; its antipruritic effect is also remarkably highMixing the known avenanthramide with diphenhydramine as positive control drug; significant technical advances are made.
The present invention also provides a composition comprising oat bran phenolic amide alkaloid-3 and oat bran phenolic amide alkaloid-4; wherein, the weight ratio of the oat bran phenolic amide alkaloid-3 to the oat bran phenolic amide alkaloid-4 is 1-5:1;
further preferably, the weight ratio of oat bran phenolic amide alkaloid-3 to oat bran phenolic amide alkaloid-4 is 2-4:1;
most preferably, the weight ratio of oat bran phenolic amide alkaloid-3 to oat bran phenolic amide alkaloid-4 is 3:1.
The inventors have surprisingly found in further studies that: a synergistic antipruritic effect may be produced without any combination of the compounds; however, when oat bran phenol amide alkaloid-3 and oat bran phenol amide alkaloid-4 are combined, the oat bran phenol amide alkaloid-3 and oat bran phenol amide alkaloid-4 can generate synergistic itching relieving effect, and the itching relieving effect is obviously higher than that of the oat bran phenol amide alkaloid-3 or the oat bran phenol amide alkaloid-4.
The invention also provides a preparation method of the oat bran phenolic amide alkaloid, which is prepared from caffeic acid analogues and 4- (2-amino ethyl) phenol as raw materials;
the caffeic acid analogues have the following structures:
wherein R is 1 、R 2 、R 3 Independently selected from H, OH or OCH 3 。
Preferably, the molar ratio of caffeic acid analog to 4- (2-aminoethyl) phenol is 1:1-3.
Preferably, the reaction substrate caffeic acid analogue is taken, an organic solvent is added, 4- (2-amino ethyl) phenol and triethylamine are added under stirring, and HATU is added after 3-6 minutes; after the addition is finished, continuing to react for 3 to 6 hours at room temperature, and monitoring the disappearance of the reaction raw materials by TLC; stopping stirring, evaporating the solvent under reduced pressure, and purifying the residue by silica gel column chromatography to obtain the oat bran phenolic amide alkaloid.
Preferably, the organic solvent, triethylamine and the reaction substrate caffeic acid analogue are used in a ratio of 30-60 mL:5-6 mL:4.5-5.0 g:1g.
Most preferably, the organic solvent, triethylamine and HATU are used in a ratio of 40ml to 5.5ml to 4.85g to 1g reaction substrate caffeic acid analog.
The invention also provides application of the compound or the composition in preparing antipruritic products; the product comprises a medicine, a skin care product or a cosmetic.
Preferably, the itch is one caused by dermatitis, burns, eczema, urticaria, xerosis cutis, superficial fungal infections or psoriasis.
Preferably, the itch is itch caused by diabetes, cholestasis, chronic kidney disease, tumor or AIDS.
The beneficial effects are that: (1) The oat bran phenolic amide alkaloid compound can obviously inhibit excessive secretion of inflammatory cytokines of skin itch mice; (2) The oat bran phenolic amide alkaloid compound can obviously reduce the scratching times of skin itching mice; (3) In particular to oat bran phenol amide alkaloid-3 and a composition formed by combining oat bran phenol amide alkaloid-3 and oat bran phenol amide alkaloid-4, wherein the anti-inflammatory and antipruritic activity of the composition is stronger than that of diphenhydramine and a known compound oat alkaloid; the oat bran amide alkaloids or compositions thereof may therefore be used for developing antipruritic products; (4) The method has the characteristics of rapid reaction, simple steps, high yield, high product purity, economy and applicability.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, and it is obvious that the drawings in the following description are only drawings of some embodiments of the present invention, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a graph of oat bran phenolic amide alkaloid compound-1 1 H-NMR spectrum.
FIG. 2 is a graph of oat bran phenolic amide alkaloid compound-1 13 C-NMR spectrum.
FIG. 3 is a oat bran phenolic amide alkaloid compound-2 1 H-NMR spectrum.
FIG. 4 is a graph of oat bran phenolic amide alkaloid compound-2 13 C-NMR spectrum.
FIG. 5 is a graph of oat bran phenolic amide alkaloid compound-3 1 H-NMR spectrum.
FIG. 6 is a graph of oat bran phenolic amide alkaloid compound-3 13 C-NMR spectrum.
FIG. 7 is a oat bran phenolic amide alkaloid compound-4 1 H-NMR spectrum.
FIG. 8 is a graph of oat bran phenolic amide alkaloid compound-5 13 C-NMR spectrum.
FIG. 9 is a graph of oat bran phenolic amide alkaloid compound-5 1 H-NMR spectrum.
FIG. 10 is a graph of oat bran phenolic amide alkaloid compound-5 13 C-NMR spectrum.
FIG. 11 is a graph of oat bran phenolic amide alkaloid compound-6 1 H-NMR spectrum.
FIG. 12 is a graph of oat bran phenolic amide alkaloid compound-6 13 C-NMR spectrum.
Detailed Description
The technical scheme of the present invention will be clearly and completely described in the following examples. It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1:
preparation of oat bran phenol amide alkaloid compound-1 (abbreviated as PAA-1) compound
(E) -3- (4-hydroxy-3-methoxyphenyl) acrylic acid (1.0 g) was weighed into a 100mL clean round bottom flask, magneton was placed, 40mL anhydrous dichloromethane was added, 4- (2-aminoethyl) phenol (1.84 g) and triethylamine (5.5 mL) were added with stirring, and HATU (4.85 g) was added after 5 minutes. After the addition was completed, the reaction was continued at room temperature for 5 hours, and TLC monitored the disappearance of the starting material. Stopping stirring, evaporating solvent under reduced pressure, subjecting the residue to silica gel column chromatography (200-300 mesh), and purifying to obtain oat bran phenolic amide alkaloid compound-1. The structure is as follows:
example 2:
preparation of oat bran phenol amide alkaloid compound-2 (abbreviated as PAA-2) compound
(E) -3- (4-hydroxyphenyl) acrylic acid (1.0 g) was weighed into a 100mL clean round bottom flask, the magneton was placed in 40mL dry dichloromethane, 4- (2-aminoethyl) phenol (1.84 g) and triethylamine (5.5 mL) were added with stirring, and after 5 minutes HATU (4.85 g) was added. After the addition was completed, the reaction was continued at room temperature for 5 hours, and TLC monitored the disappearance of the starting material. Stopping stirring, evaporating solvent under reduced pressure, subjecting the residue to silica gel column chromatography (200-300 mesh), and purifying to obtain oat bran phenolic amide alkaloid compound-2. The structure is as follows:
example 3:
preparation of oat bran phenol amide alkaloid compound-3 (abbreviated as PAA-3) compound
(E) -3- (3, 4-dihydroxyphenyl) acrylic acid (1.0 g) was weighed into a 100mL clean round bottom flask, magneton was placed, 40mL anhydrous dichloromethane was added, 4- (2-aminoethyl) phenol (1.84 g) was added with stirring, triethylamine (5.5 mL) was added, and HATU (4.85 g) was added after 5 minutes. After the addition was completed, the reaction was continued at room temperature for 5 hours, and TLC monitored the disappearance of the starting material. Stopping stirring, evaporating solvent under reduced pressure, subjecting the residue to silica gel column chromatography (200-300 mesh), and purifying to obtain oat bran phenolic amide alkaloid compound-3. The structure is as follows:
example 4:
preparation of oat bran phenol amide alkaloid compound-4 (abbreviated as PAA-4) compound
(E) -3- (3, 4-dihydroxyphenyl) acrylic acid (1.0 g) was weighed into a 100mL clean round bottom flask, magneton was placed, 40mL anhydrous dichloromethane was added, 4- (2-aminoethyl) phenol (1.84 g) was added with stirring, triethylamine (5.5 mL) was added, and HATU (4.85 g) was added after 5 minutes. After the addition was completed, the reaction was continued at room temperature for 5 hours, and TLC monitored the disappearance of the starting material. Stopping stirring, evaporating solvent under reduced pressure, subjecting the residue to silica gel column chromatography (200-300 mesh), and purifying to obtain oat bran phenolic amide alkaloid compound-4. The structure is as follows:
example 5:
preparation of oat bran phenol amide alkaloid compound-5 (abbreviated as PAA-5) compound
(E) -3- (4-hydroxy-3-methoxyphenyl) acrylic acid (1.0 g) was weighed into a 100mL clean round bottom flask, magneton was placed, 40mL anhydrous dichloromethane was added, 4- (2-aminoethyl) -2-methoxyphenyl (1.84 g) was added with stirring, triethylamine (5.5 mL) was added after 5 minutes, HATU (4.85 g). After the addition was completed, the reaction was continued at room temperature for 5 hours, and TLC monitored the disappearance of the starting material. Stopping stirring, evaporating solvent under reduced pressure, subjecting the residue to silica gel column chromatography (200-300 mesh), and purifying to obtain oat bran phenolic amide alkaloid compound-5. The structure is as follows:
example 6:
preparation of oat bran phenol amide alkaloid compound-6 (abbreviated as PAA-6) compound
(E) -3- (4-hydroxy-3, 5-dimethoxyphenyl) acrylic acid (1.0 g) was weighed into a 100mL clean round bottom flask, magneton was placed, 40mL anhydrous dichloromethane was added, 4- (2-aminoethyl) phenol (1.84 g) and triethylamine (5.5 mL) was added with stirring, and HATU (4.85 g) was added after 5 minutes. After the addition was completed, the reaction was continued at room temperature for 5 hours, and TLC monitored the disappearance of the starting material. Stopping stirring, evaporating solvent under reduced pressure, subjecting the residue to silica gel column chromatography (200-300 mesh), and purifying to obtain oat bran phenolic amide alkaloid compound-6. The structure is as follows:
experimental example:
the invention uses a mouse skin itch model inhibition experiment to prove that the oat bran phenol amide alkaloid compound and the composition have itching relieving activity. The content of IL-1 beta, IL-4, PAR-2 and P substances in serum is detected by an ELISA method.
The oat bran phenol amide alkaloid compound and the antipruritic activity of the composition
Kunming mice, SPF grade, male, body weight (35+ -2) g, constant temperature (20+ -2) deg.C, humidity 40% -70%, feeding environment for 12h (7:00-19:00) of light rhythm, free feeding, and adaptive feeding for 1 week. The mice are randomly divided into a normal group, a skin itch model group, a diphenhydramine group, an oat alkaloid group, an oat bran phenol amide alkaloid compound-1-6 groups and an oat bran phenol amide alkaloid compound composition group (the mass ratio of the oat bran phenol amide alkaloid compound-3 to the oat bran phenol amide alkaloid compound-4 is 1:1), wherein each group comprises 10 mice. After the start of the experiment, the mice of each group except the normal group were subcutaneously injected with 125/mg.kg of D-galactose injection from the cervical back of each group for 6 weeks (normal group was given the same dose of physiological saline). Starting at week 7, mice in each drug group were dosed at 0.5mg/cm 2 Is applied by 1 time in evening every day for 7 days (normal group, skin aging pruritus model group dailyThe same dose of distilled water was administered). During the experiment, the scissors on the back of the neck of the mouse shave hair, and the hair on the back of the neck is kept free.
TABLE 1 influence of oat bran phenol amide alkaloid compounds on mouse pruritus latency and pruritus frequency
Note that compared with the skin itch model group * p＜0.05, ** p＜0.01.
As can be seen from the experimental data in table 1, oat bran phenolic amide alkaloid compound-3 (PAA-3), which has significantly longer incubation time for pruritus in mice than other oat bran phenolic amide alkaloid compounds, as well as the known oat alkaloid and positive control drug diphenhydramine; the pruritus frequency of the oat bran phenol amide alkaloid compound is obviously less than that of other oat bran phenol amide alkaloid compounds, and the oat alkaloid and a positive control drug diphenhydramine are known. This illustrates: r in the compound of the formula I or the structure shown in the formula II 1 、R 2 And R is 3 Oat bran phenolic amide alkaloids obtained after substitution by different groups, the antipruritic effect of which is greatly different; the itching relieving effect of the oat bran phenolic amide alkaloid-3 is far greater than that of other compounds, and has very remarkable itching relieving effect; the antipruritic effect is obviously higher than that of the known oat alkaloid and the positive control drug diphenhydramine; significant technical advances are made.
As can also be seen from the experimental data in table 1, when oat bran phenol amide alkaloid-3 and oat bran phenol amide alkaloid-4 are combined, the antipruritic effect is significantly higher than that of either oat bran phenol amide alkaloid-3 or oat bran phenol amide alkaloid-4 alone; is also obviously higher than the known avenanthramide and the positive control drug diphenhydramine; this demonstrates that oat bran phenolic amide alkaloid-3 and oat bran phenolic amide alkaloid-4, when combined, produce synergistic antipruritic effects.
Furthermore, we tested the effect of oat bran phenolic amide alkaloid compound-3 (PAA-3) of the present invention on IL-1β, IL-4, PAR-2, substance P: the occurrence of cutaneous pruritus is related to immune cells (eosinophils, mast cells, etc.) and inflammatory factors (interleukins, histamine, etc.). Mast cells are widely present around the blood vessels of skin and tissues and contain inflammatory factors such as histamine, heparin, 5-hydroxytryptamine, etc., and mast cells and the above-mentioned inflammatory factors play an important role in the induction of allergies. In addition, IL-1β and IL-4 are common inflammatory factors in diseases, and PAR is a member of the G protein-coupled receptor family. PAR-2 can promote vascular endothelial leukocyte adhesion migration, promote expression and release of IL-1 and the like, and has important pro-inflammatory effect and tissue injury mediating effect. Meanwhile, PAR-2 may stimulate mast cells to secrete IL-4. Thus, after 1h of application on day 7, 0.025% low molecular dextran-40 injection was intravenously injected and after 30min, the camera recorded the mouse scratch performance. Blood is collected from eyeballs, and the mixture is centrifuged for 10min at 3000r/min, so that serum is collected, and the content of IL-1 beta, IL-4, PAR-2 and P substances in the serum is detected by an enzyme-linked immunosorbent assay.
TABLE 2 Effect of oat bran phenol amide alkaloid compound-3 on mouse IL-1 beta, IL-4
Note comparison with the normal group # p＜0.05, ## p is less than 0.01; comparison with the skin itch model group * p＜0.05, ** p＜0.01.
TABLE 3 Effect of oat bran phenolic amide alkaloid compound-3 on mouse serum PAR-2
Note comparison with the normal group # p＜0.05, ## p is less than 0.01; comparison with the skin itch model group * p＜0.05, ** p＜0.01.
TABLE 4 influence of oat bran phenol amide alkaloid compound-3 on mouse serum substance P
Note comparison with the normal group # p＜0.05, ## p is less than 0.01; comparison with the skin itch model group * p＜0.05, ** p＜0.01.
As can be seen from the data in table 2, the skin itch model group showed an increased IL-1 beta significance and a decreased IL-4 significance compared to the normal group. Compared with the skin itch model group, the oat bran phenol amide alkaloid compound-3 group has obviously reduced IL-1 beta and obviously increased IL-4 after administration, which indicates that the oat bran phenol amide alkaloid compound-3 has the effect of relieving skin itch. As can be seen from the data in table 3, the skin itch model group had a significantly increased PAR-2 content compared to the normal group. After administration, compared with the skin itch model group, the content of PAR-2 in the oat bran phenolic amide alkaloid compound-3 group is obviously reduced. As can be seen from the data in table 4, the skin itch model group P was significantly elevated compared to the normal group. After administration, the oat bran phenolic amide alkaloid compound-3 group P substance was significantly reduced compared to the skin itch model group.
The deep mechanism research is explained; the oat bran phenolic amide alkaloid compound or composition may be used for relieving itching by regulating PAR-2 and substance P expression to reduce, inflammatory cytokine secretion to reduce.
The foregoing disclosure is illustrative of the preferred embodiments of the present invention, and is not to be construed as limiting the scope of the invention, as it is understood by those skilled in the art that all or part of the above-described embodiments may be practiced with equivalents thereof, which fall within the scope of the invention as defined by the appended claims.

Claims (2)

1. A composition comprising oat bran phenolic amide alkaloid-3 and oat bran phenolic amide alkaloid-4; wherein, the weight ratio of the oat bran phenolic amide alkaloid-3 to the oat bran phenolic amide alkaloid-4 is 1:1;
the structural formulas of oat bran phenol amide alkaloid-3 and oat bran phenol amide alkaloid-4 are as follows:
oat bran phenolic amide alkaloid-3;
oat bran phenolic amide alkaloid-4.
2. Use of the composition of claim 1 for the preparation of an antipruritic product; the product comprises a medicament or a cosmetic.
CN202210248498.8A 2022-03-14 2022-03-14 Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products Active CN114539092B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210248498.8A CN114539092B (en) 2022-03-14 2022-03-14 Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210248498.8A CN114539092B (en) 2022-03-14 2022-03-14 Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products

Publications (2)

Publication Number Publication Date
CN114539092A CN114539092A (en) 2022-05-27
CN114539092B true CN114539092B (en) 2023-11-17

Family

ID=81663491

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210248498.8A Active CN114539092B (en) 2022-03-14 2022-03-14 Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products

Country Status (1)

Country Link
CN (1) CN114539092B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101401850A (en) * 2008-11-11 2009-04-08 江西本草天工科技有限责任公司 Piper hancei total alkaloid extract and uses thereof
KR101310980B1 (en) * 2013-02-18 2013-09-25 주식회사 내추럴솔루션 The cosmetics and functional food composition for improving anti-oxidant, anti-inflammatory and anti-wrinkling containing lycium chinense mill stem extracts
CN103508919A (en) * 2012-06-25 2014-01-15 复旦大学 Alkaloid compound and use of the same in preparation of anti-complement drugs
CN107805257A (en) * 2017-09-12 2018-03-16 烟台大学 A kind of capsule of weeping forsythia alkaloid extract and its preparation method and application
CN115417788A (en) * 2022-08-31 2022-12-02 中国人民解放军空军军医大学 Anti-inflammatory compound and preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892923B1 (en) * 2005-11-08 2009-01-16 Engelhard Lyon Sa USE OF PARA-COUMARIC OR PARA-HYDROXYCINNAMIC ACID DERIVATIVES IN COSMETIC OR DERMATOLOGICAL COMPOSITIONS.
US20200289458A1 (en) * 2017-09-22 2020-09-17 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101401850A (en) * 2008-11-11 2009-04-08 江西本草天工科技有限责任公司 Piper hancei total alkaloid extract and uses thereof
CN103508919A (en) * 2012-06-25 2014-01-15 复旦大学 Alkaloid compound and use of the same in preparation of anti-complement drugs
KR101310980B1 (en) * 2013-02-18 2013-09-25 주식회사 내추럴솔루션 The cosmetics and functional food composition for improving anti-oxidant, anti-inflammatory and anti-wrinkling containing lycium chinense mill stem extracts
CN107805257A (en) * 2017-09-12 2018-03-16 烟台大学 A kind of capsule of weeping forsythia alkaloid extract and its preparation method and application
CN115417788A (en) * 2022-08-31 2022-12-02 中国人民解放军空军军医大学 Anti-inflammatory compound and preparation method and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Characterization and profiling of phenolic amides from Cortex Lycii by ultra-high performance liquid chromatography coupled with LTQ-Orbitrap mass spectrometry;Jingxian Zhang等;《Analytical and bioanalytical chemistry》;第407卷;第581-595页 *
Cinnamoylphenethylamine 1H-NMR chemical shifts: a concise reference for ubiquitous compounds;Pedersen, Hans A等;《Natural Product Communications》;第05卷(第08期);第1259-1262页 *
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4+ cells;Choi, E. J等;《Journal of Enzyme Inhibition and Medicinal Chemistry》;第34卷(第01期);第613-619页 *

Also Published As

Publication number Publication date
CN114539092A (en) 2022-05-27

Similar Documents

Publication Publication Date Title
JP3114895B2 (en) Pharmaceutical preparations for the treatment of inflammatory diseases
EP2878305A1 (en) Pharmaceutical composition for preventing or treating stat3-mediated disease, comprising salvia plebeia r. br. extract or fraction thereof as active ingredientcomposition pharmaceutique pour la prévention ou le traitement de maladies médiées par stat-3, contenant un extrait ou une fraction de salvia plebeia r. br. en tant que principe actif
Chen et al. The protective effects of 18β-Glycyrrhetinic acid on Imiquimod-Induced psoriasis in mice via suppression of mTOR/STAT3 signaling
KR101510936B1 (en) Composition comprising extract of Martensia bibarii for prevention and treatment of autoimmune disease or inflammatory disease
CN114539092B (en) Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products
WO2018175334A1 (en) Compositions and methods for skin treatments
KR101514257B1 (en) Pharmaceutical Composition and Quasi-Drug Cosmetic Using Same
JP5923375B2 (en) CGRP response promoter
ES2941463T3 (en) Compositions for the treatment of atopic dermatitis
JP2007031302A (en) Adiponectin production accelerator and metabolic syndrome preventive
US9540378B2 (en) Composition comprising purine derivatives or salt thereof for preventing or treating atopic dermatitis
JP4381495B2 (en) MCP-1 receptor antagonist comprising organic germanium compound as active ingredient, and preventive or therapeutic agent for inflammatory disease and organ disorder involving MCP-1
AU2017346183B2 (en) Composition for preventing or treating psoriasis containing monoacetyl diacylglycerol compound
JP2010202569A (en) Antiallergic and anti-inflammatory composition
JP2020117488A (en) Method for treating inflammatory disorder
JP7396585B2 (en) Composition for suppressing TSLP gene expression, suppressing IL-33 gene expression, or promoting filaggrin production
KR101606885B1 (en) Pharmaceutical composition for preventing and treating allergic disease comprising adenine or pharmaceutically acceptable salt thereof as an active ingredient
KR20010086473A (en) Composition of essential oil having an inhibitary activity on the formation of leucotriens
KR102532055B1 (en) Composition comprising dihydrofuran-2-one derivative for treating inflammatory disease
WO2024050434A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
TW202408482A (en) Plectranthus amboinicus extract for use in inhibiting immune responses
CN115381818A (en) Method for promoting autophagy degradation function of cells and application
WO2013085346A1 (en) Novel phytosphingosine derivatives, and composition comprising same for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratosis diseases
CN117482104A (en) Application of astragalus polysaccharide as programmed necrosis inhibitor
JP2015054832A (en) Filaggrin production promoter

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant